nach oben

hautnah

Erschienen in:

06.09.2019 | Neurodermitis | Atopische Dermatitis

Therapie der atopischen Dermatitis

Zahlreiche Biologika in der Pipeline

verfasst von: Prof. Dr. Thomas Werfel

Erschienen in: hautnah | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Anti-IL-22-Antikörper, Januskinase-Inhibitoren und H4-Rezeptor-Blocker könnten in Zukunft das Therapiearsenal gegen schwere Neurodermitisformen erweitern.

Vorheriger Artikel Gezielter Einsatz

Nächster Artikel Unzureichender Tetanusimpfschutz bei Psoriasis und systemischer Immunsuppression

Gerbens LAA et al (2018) Methotrexate and azathioprine for severe atopic dermatitis: a 5‑year follow-up study of a randomized controlled trial. Br J Dermatol 178:1288–1296CrossRef

van der Schaft J et al (2015) Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172:1621–1627CrossRef

Guttman-Yassky E et al (2018) Dupilumab progressively improves systemic and 4. cutaneous abnormalities in atopic dermatitis patients. J Allergy Clin Immunol:k4. https://doi.org/10.1016/j.jaci.2018.08.022 CrossRefPubMed

Werfel T (2018) Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 201 7/2018. Curr Opin Allergy Clin Immunol 18:432–437CrossRef

Werfel T et al (2018) New aspects in systemic treatment of atopic dermatitis. Hautarzt 69:217–224CrossRef

de Bruin-Weller M et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo- controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 178:1083– 1101CrossRef

Blauvelt A et al (2019) Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo- controlled trial in adults with moderate- to-severe atopic dermatitis. J Am Acad Dermatol 80:158–167CrossRef

Rabe KF et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485CrossRef

Castro M et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496CrossRef

10.

Wollenberg A et al (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6:1778–1780CrossRef

11.

Treister AD et al (2018) Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154:1208–1211CrossRef

12.

Ruzicka T et al (2017) Anti-Interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 376:826–835CrossRef

13.

Kabashima K et al (2018) Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol 142(4):121–130CrossRef

14.

Wollenberg A et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL - 13 mAb. J Allergy Clin Immunol 143:135–141CrossRef

15.

Simpson EL et al (2018) Efficacy and safety of lebrikizumab (an anti-IL - 13 monoclonal antibody) in adults with moderate-to- severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863–871CrossRef

16.

Guttman-Yassky E et al (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78:872–881CrossRef

17.

Brunner PM et al (2019) Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol 143:142–154CrossRef

18.

Guttman-Yassky E et al (2018) IL - 17C: a unique epithelial C ytokine with potential for  targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol 138:1467–1469CrossRef

19.

Schaper-Gerhardt K et al (2018) Histamine H 4 receptor and skin disorders. Br J Pharmacol

20.

Werfel TLV, Asher A et al (2018) Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in atopic dermatitis. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2018.07.047 CrossRefPubMed

21.

Guttman-Yassky E et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80(4):913–921.e9CrossRef

Titel: Therapie der atopischen Dermatitis
Zahlreiche Biologika in der Pipeline
verfasst von: Prof. Dr. Thomas Werfel
Publikationsdatum: 06.09.2019
Verlag: Springer Vienna
Schlagwort: Neurodermitis
Erschienen in: hautnah / Ausgabe 4/2019
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI: https://doi.org/10.1007/s12326-019-00346-w

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Kontaminierte Kosmetika

Unzureichender Tetanusimpfschutz bei Psoriasis und systemischer Immunsuppression

Alles zur Erkrankung auf einen Blick

Melanom: eosinophiles kationisches Protein als Prognosemarker?

Menschen mit Psoriasis in Österreich

B-Lymphozyten sind entscheidend für erfolgreiche Immuntherapie